Feedback / Questions
LUT014 - Lutris Pharma
https://www.prnewswire.com/il/news-releases/lutris-pharma-presents-additional-positive-data-from-its-phase-2-trial-of-lut014-gel-demonstrating-significant-efficacy-in-treating-acneiform-rash-associated-with-use-of-anti-egfr-cancer-therapies-at-the-esmo-gastrointestinal-canc-302498945.html
Jul 7, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next